Introduction
============

Patients with sepsis have a mortality rate of 30%--40% across the world.[@b1-cia-12-917] As a primary cause of death not only in Western countries but also in China, sepsis is diagnosed as abnormal organ functions as a result of a disordered response to a severe infection.[@b2-cia-12-917] Its most severe appearance is septic shock because of circulatory disturbance and metabolic abnormalities.[@b3-cia-12-917] Levosimendan (Qilu Pharmaceutical, Jinan, People's Republic of China) is a new kind of calcium-sensitizing agent that has the potential to improve the cardiovascular function and blood circulation without obviously increasing the oxygen demand and impairing the diastolic relaxation.[@b4-cia-12-917]--[@b6-cia-12-917] Moreover, previous studies have suggested that levosimendan improves the pulmonary, renal, liver, and coagulation functions.[@b7-cia-12-917]--[@b9-cia-12-917] Clinical data on the application of levosimendan in Chinese patients with sepsis have been scarce and controversial, and it is essential to perform a prospective study to evaluate the curative value of levosimendan in Chinese elderly patients with sepsis.[@b10-cia-12-917] Besides, a recent study that investigated the effect of levosimendan at an infusion rate of 0.2--0.4 μg/kg/min or with a loading dose did not reach a satisfactory conclusion.[@b11-cia-12-917] The present study was designed to assess the effect of small-dose levosimendan (0.1--0.2 μg/kg/min) without a loading dose on mortality rates and organ functions in Chinese elderly patients with sepsis.

Methods
=======

Participants and procedures
---------------------------

Following a prospective, randomized, and double-blinded design, 240 Chinese patients 65 years old or older with septic shock were admitted to the intensive care unit (ICU) between June 2012 and December 2016. Septic shock was diagnosed on the basis of the following criterion: patients with agents to maintain the mean arterial pressure of at least 65 mmHg in spite of appropriate volume resuscitation. The exclusion criteria were pregnancy, significant valvular heart disease, present or suspected acute coronary syndrome, and limitations to the use of inotropes such as ventricular outflow tract obstruction and mitral valve systolic anterior motion ([Figure 1](#f1-cia-12-917){ref-type="fig"}). The study protocol was approved by the Ethics Committee of Daqing Oilfield General Hospital. Each participant provided written informed consent to be included in the study. All patients were randomly and evenly assigned into a levosimendan group (number of patients =120) and a control group (number of patients =120) using computer-generated random numbers in a randomized block design. The control group underwent standard care, and the levosimendan group was administered levosimendan (Specifications: 5 mL, 12.5 mg) at a continuous intravenous infusion rate of 0.1--0.2 μg/kg/min without a loading dose for 24 hours in addition to standard care.

Follow-up and end points
------------------------

The mean daily sequential organ failure assessment (SOFA) Score of patients in ICU was the end point followed up from randomization to a maximum of 28 days.[@b12-cia-12-917] The daily SOFA score was calculated for each patient on the basis of five organ scores: cardiovascular, respiratory, liver, renal, and coagulation functions (scores for each organ range from 0 to 4, with higher scores indicating more severe abnormality of organ functions; maximum score, 20). Because of the difficulty in accurately scoring the Glasgow Coma Score daily in the presence of sedation, the Glasgow Coma Score was not recommended by previous studies[@b13-cia-12-917],[@b14-cia-12-917] and was not applied in the present study. Daily scores were totaled and divided by the number of days of ICU stay in order to calculate the mean daily SOFA score. Not only the mortality rates at 28 days, at ICU discharge, and at hospital discharge, but also the number of days of ICU and hospital stay, were recorded and compared between the two groups. All patients continually received the assigned agents and were not lost during the follow-up.

Description and statistics
--------------------------

Continuous variables with normal distribution were reported using mean and standard deviation, and the difference between the two groups was compared using Student's *t*-test. Continuous variables with abnormal distribution were reported using median and interquartile range, and the difference between the two groups was compared using the Mann--Whitney U test. Categorical variables were reported with number and percentage, and the difference between the two groups was compared with the *χ*^2^ test. Statistical analyses were carried out by the Statistical Package for Social Science (SPSS) version 17.0 software (SPSS Inc., Chicago, IL, USA), and a *P*-value \<0.05 was accepted as statistically significant.

Results
=======

Participants, comprising 134 males (55.8%) and 106 females (44.2%), were 70 (67--73) years old. As shown in [Table 1](#t1-cia-12-917){ref-type="table"}, baseline characteristics, preexisting illnesses, initial infections, organ failures, and additional agents and therapies showed no significant difference between the two groups (*P*\>0.05 for all). As shown in [Table 2](#t2-cia-12-917){ref-type="table"}, there were no significant differences in mortality rates at 28 days, at ICU discharge, and at hospital discharge between the two groups (*P*\>0.05 for all). The number of days of ICU and hospital stay was significantly less in the levosimendan group than in the control group (*P*\<0.05 for all). The mean daily total SOFA score and all organ scores except the cardiovascular scores showed no significant difference between the two groups (*P*\>0.05 for all). Cardiovascular scores in the levosimendan group were significantly higher than those in the control group (*P*\<0.05 for all).

Discussion
==========

As a new kind of calcium-sensitizing agent, levosimendan has the ability to improve the cardiovascular function through the selective combination with myocardial troponin C, and the effective stabilization of Ca^2+^-dependent interaction between cardiac troponin I and cardiac troponin T.[@b4-cia-12-917] Levosimendan can be combined with cardiac troponin C zsitivity to Ca^2+^, leading to myocardial contraction even at the same or lower Ca^2+^ concentration.[@b15-cia-12-917] Levosimendan has no obvious effect on oxygen demand and diastolic relaxation without disturbing the metabolism of cyclic adenosine monophosphate.[@b5-cia-12-917] By sensitizing cardiomyocytes to existing levels of intracellular calcium, an increase in the force of myocardial contraction is achieved with a minimal increase in myocardial oxygen demand.[@b16-cia-12-917] Previous studies have suggested that levosimendan has the potential to provide the beneficial cardioprotective and hemodynamic effects not only in the cardiovascular field but also in patients with sepsis.[@b17-cia-12-917] The treatment of sepsis with levosimendan should be specially considered in Chinese elderly patients. However, few researchers have paid attention to the curative value of levosimendan, and there have been few and controversial studies on the application of levosimendan in Chinese patients with sepsis. In the present study, although levosimendan could not reduce the mortality rates, it succeeded in shortening the days of ICU and hospital stay in Chinese elderly patients with sepsis. Sepsis is a complicated inflammation caused by infection, and with levosimendan, it is difficult to increase the survival of patients with sepsis. Hence, this is not a surprising result in the present study. Combining levosimendan with anti-inflammatory compounds and supportive treatments may offer a higher chance of curing the patients and improving their survival.

Meanwhile, previous studies have shown a potential benefit of levosimendan on cardiovascular, pulmonary, renal, hepatic, and coagulation functions in patients with sepsis.[@b6-cia-12-917]--[@b9-cia-12-917] As an inotropic agent, levosimendan has also appeared to play anti-inflammatory, antioxidative, and antiapoptotic roles, and alleviate the ischemia and reperfusion damage.[@b18-cia-12-917]--[@b21-cia-12-917] Studies that have examined the effect of levosimendan on organ functions have been scarce and controversial, and further studies are necessary to investigate this problem in Chinese elderly patients with sepsis. However, the current study found no evidence of any beneficial effect on the pulmonary, renal, hepatic, and coagulation functions, but confirmed that cardiovascular function was improved in the levosimendan group compared with that in the control group, and that the application of levosimendan improved cardiovascular function.

A recent study that investigated the effect of levosimendan at an infusion rate of 0.2--0.4 μg/kg/min or with a loading dose did not reach a satisfactory conclusion.[@b11-cia-12-917] Peripheral vascular resistance and multiple organ perfusion excessively lowered by high-dose levosimendan are of no benefit to the improvement of organ functions and mortality rates in patients with sepsis.[@b10-cia-12-917] In the present study, levosimendan was administered through a continuous intravenous infusion of 0.1--0.2 μg/kg/min without a loading dose rather than 0.2--0.4 μg/kg/min with a loading dose. In clinical practice, the present study has demonstrated the significant benefit of small-dose levosimendan in maintaining stable hemodynamics, and the curative value of small-dose levosimendan for Chinese elderly patients with sepsis, suggesting that this kind of usage is appropriate for Chinese patients with sepsis.

Conclusion
==========

In the present study, small-dose levosimendan could not reduce the mortality rates or enhance the respiratory, hepatic, renal, and coagulation functions, but succeeded in shortening the number of days of ICU and hospital stay and improving the cardiovascular function, which suggests that small-dose levosimendan is valuable for Chinese elderly patients with sepsis.
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###### 

Baseline characteristics of patients with sepsis in the levosimendan and control groups

  ----------------------------------------------------------------------------------------------
  Characteristics                             Levosimendan group\   Control group\   *P*-value
                                              (n=120)               (n=120)          
  ------------------------------------------- --------------------- ---------------- -----------
  Age (years), median (interquartile range)   70 (67--74)           69 (67--73)      0.361

  Males, n (%)                                69 (57.5)             65 (54.2)        0.603

  Preexisting illnesses, n (%)                                                       

   Ischemic heart disease                     18 (15.0)             13 (10.8)        0.336

   Heart failure                              11 (9.2)              9 (7.5)          0.640

   Severe COPD                                12 (10.0)             9 (7.5)          0.493

   Chronic renal failure                      12 (10.0)             13 (10.8)        0.833

   Cirrhosis                                  5 (4.2)               3 (2.5)          0.719

   Diabetes                                   32 (26.7)             27 (22.5)        0.454

   Recent surgery                             41 (34.2)             47 (39.2)        0.422

  Initial infections, n (%)                                                          0.533

   Lung                                       51 (42.5)             44 (36.7)        

   Abdomen                                    39 (32.5)             43 (35.8)        

   Urinary tract                              8 (6.7)               13 (10.8)        

   Soft tissue or catheter                    3 (2.5)               2 (1.7)          

   Neurologic site                            2 (1.7)               6 (5.0)          

   Primary bacteremia                         6 (5.0)               5 (4.2)          

   Other                                      11 (9.2)              7 (5.8)          

  Organ failures, n (%)                                                              

   Respiratory                                51 (42.5)             49 (40.8)        0.793

   Liver                                      5 (4.2)               7 (5.8)          0.554

   Renal                                      37 (30.8)             41 (34.2)        0.581

   Neurologic                                 59 (49.2)             56 (46.7)        0.698

   Coagulation                                9 (7.5)               7 (5.8)          0.605

  Additional agents and therapies, n (%)                                             

   Epinephrine                                11 (9.2)              12 (10.0)        0.826

   Norepinephrine                             63 (52.5)             59 (49.2)        0.606

   Dopamine                                   74 (61.7)             71 (59.2)        0.692

   Dobutamine                                 19 (15.8)             24 (20)          0.400

   Mechanical ventilation                     89 (74.2)             83 (69.2)        0.390

   Renal replacement therapy                  21 (17.5)             25 (20.8)        0.512
  ----------------------------------------------------------------------------------------------

**Abbreviation:** n, number of patients.

###### 

Mortality rates and organ functions of patients with sepsis in the levosimendan and control groups

  ----------------------------------------------------------------------------------------------------------------
  Outcomes                                                      Levosimendan group\   Control group\   *P*-value
                                                                (n=120)               (n=120)          
  ------------------------------------------------------------- --------------------- ---------------- -----------
  Mortality rates, n (%)                                                                               

   At 28 days                                                   33 (27.5)             39 (32.5)        0.398

   At ICU discharge                                             24 (20.0)             28 (23.3)        0.531

   At hospital discharge                                        36 (30.0)             44 (36.7)        0.273

   Intensive care unit stay, days                               17 (13--22)           20 (14--23)      0.034

   Hospital stay, days                                          24 (22--30)           28 (22--31)      0.042

   Mean daily total sequential organ failure assessment score   8 (0--12)             8 (2--13)        0.249

   Cardiovascular                                               2 (0--3)              2 (1--3)         0.046

   Respiratory                                                  2 (0--3)              2 (1--3)         0.208

   Liver                                                        1 (0--2)              1 (0--2)         0.332

   Renal                                                        2 (0--2)              2 (0--3)         0.366

   Coagulation                                                  1 (0--2)              1 (0--2)         0.402
  ----------------------------------------------------------------------------------------------------------------

**Abbreviations:** ICU, intensive care unit; n, number of patients.
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